Metropolis Healthcare Posts Robust FY26 Results, Profit Soars 31%

Consolidated Revenue: ₹1,645.85 crore for FY2026 vs ₹1,346.32 crore for FY2025.
Profit After Tax: ₹190.02 crore for FY2026 vs ₹145.51 crore for FY2025.

Reader Takeaway: Profit surged on revenue growth; auditor change and tax hearing are key watchpoints.

What just happened (today’s filing)

Metropolis Healthcare Ltd. has announced its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company reported strong year-on-year growth in both revenue and profitability.

A second interim dividend of Re 1 per equity share (face value Rs 2) for FY2025-26 was declared. The record date for this dividend is May 19, 2026, with payment due within 30 days.

In a significant governance update, Deloitte Haskins & Sells Chartered Accountants LLP has been appointed as the new statutory auditors for a five-year term, replacing BSR & Co. LLP.

Additionally, Dr. Nilesh Shah will transition from his role as President - Internal Assurance to an advisory position, effective May 14, 2026, ceasing to be Senior Management Personnel from May 13, 2026.

Why this matters

The strong financial performance reflects the company's ability to grow its top line and bottom line effectively in a competitive market. This growth is a positive signal for shareholders.

The appointment of a new auditor, Deloitte, signifies a refresh in corporate governance practices. It ensures compliance and adherence to regulatory standards for the upcoming years.

The declared dividend directly benefits shareholders, providing a tangible return on their investment. The upcoming ITAT hearing, however, introduces an element of uncertainty regarding potential tax liabilities.

The backstory (grounded)

Metropolis Healthcare has a track record of consistent revenue and profit growth, fueled by strategic network expansion and increasing demand for quality diagnostic services across India. This underlying growth trajectory supports the latest results.

BSR & Co. LLP had been serving as the company's statutory auditor for several years. Auditor rotation is a common practice in listed entities to ensure independence and fresh perspectives.

The company has previously faced tax demands and litigation from the Income Tax Department, leading to appearances before appellate authorities such as the Income Tax Appellate Tribunal (ITAT). This background makes the upcoming hearing particularly relevant.

What changes now

Shareholders can expect a dividend payout, providing immediate returns.

The company's financial reporting and audits will now be overseen by Deloitte Haskins & Sells for the next five years.

Corporate governance structure sees a transition in senior management with Dr. Nilesh Shah moving to an advisory role.

Uncertainty around the tax demand from the Income Tax Department will persist until the ITAT hearing concludes.

Risks to watch

The primary risk remains the outcome of the ITAT hearing scheduled for May 14, 2026, concerning tax demands raised by the Income Tax Department.

Any adverse ruling could potentially lead to financial penalties or additional liabilities, impacting profitability and cash flows.

While not a risk in itself, the change in statutory auditors always warrants monitoring for any specific observations or concerns they might raise in future reports.

Peer comparison

Metropolis Healthcare's FY26 revenue growth of approximately 22% and profit growth of 31% place it well within the competitive landscape. Peers like Dr. Lal PathLabs, the largest diagnostics chain, also focus on network expansion and service diversification. Thyrocare Technologies leverages its cost-efficient model, while Vijaya Diagnostic Centre holds a strong regional presence.

Context metrics (time-bound)

• Consolidated revenue grew from ₹1,346.32 crore in FY2025 to ₹1,645.85 crore in FY2026.
• Consolidated profit after tax rose from ₹145.51 crore in FY2025 to ₹190.02 crore in FY2026.
• Standalone revenue increased from ₹1,232.80 crore in FY2025 to ₹1,381.80 crore in FY2026.
• Standalone profit after tax climbed from ₹124.34 crore in FY2025 to ₹157.14 crore in FY2026.

What to track next

Shareholders should monitor the upcoming 26th Annual General Meeting (AGM) where the appointment of Deloitte Haskins & Sells as statutory auditors will likely be formally approved.

The outcome of the ITAT hearing on May 14, 2026, concerning the Income Tax Department's demands, is a critical trigger for financial risk assessment.

Payment of the declared interim dividend, expected by June 12, 2026, should be completed on schedule.

Future quarterly results will show the continuation of revenue and profit growth trends.